SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-21-001370
Filing Date
2021-08-12
Accepted
2021-08-12 16:18:06
Documents
14
Period of Report
2021-08-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lyel-20210812.htm   iXBRL 8-K 47325
2 EX-99.1 lyel-20210812ex99_1.htm EX-99.1 287686
3 GRAPHIC img30200343_0.jpg GRAPHIC 74529
  Complete submission text file 0000950170-21-001370.txt   570901

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lyel-20210812_pre.xml EX-101.PRE 9970
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lyel-20210812_lab.xml EX-101.LAB 13486
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lyel-20210812.xsd EX-101.SCH 2420
7 EXTRACTED XBRL INSTANCE DOCUMENT lyel-20210812_htm.xml XML 4732
Mailing Address 400 EAST JAMIE COURT SUITE 301 SOUTH SAN FRANCISCO CA 94080
Business Address 400 EAST JAMIE COURT SUITE 301 SOUTH SAN FRANCISCO CA 94080 650 695-0677
Lyell Immunopharma, Inc. (Filer) CIK: 0001806952 (see all company filings)

IRS No.: 833006753 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40502 | Film No.: 211167821
SIC: 2834 Pharmaceutical Preparations